Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran

Jalilian, Amir Reza; Beiki, Davood; Hassanzadeh-Rad, Arman; Eftekhari, Arash; Geramifar, Parham; Eftekhari, Mohammad

doi:10.1053/j.semnuclmed.2016.01.006

Cited by 12 publications

(2 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The radiopharmaceuticals provide a non-invasive mechanism for targeting the therapeutic radiations with low side effects [11]. Also, in case of diagnosis, radioactive drugs represent non-invasive imaging agents which give information about the structure and function of diseased organs or tissue [12].…”

Section: Introductionmentioning

confidence: 99%

Review About Radiopharmaceuticals: Preparation, Radioactivity, and Applications

et al. 2020

View full text Add to dashboard Cite

In the recent few decades, there was a growth in the field of radioactive medicinal agents called radiopharmaceuticals. Radiopharmaceuticals are consisting of radioactive materials called radioisotopes. Radiopharmaceuticals were recently used in both therapeutic and diagnostic purposes. More than 100 radioactive substances are used in nuclear medicine. According to the decay of radioactive substances, there are three types of radioactive decays, alpha particles, beta particles, and gamma radiations. Alpha particles consist of two protons and two neutrons with large mass and charge so it has no penetration power into the skin and has a destructive effect. Beta particles have less charge and less mass so, they can penetrate the tissue and have a less destructive effect than alpha particles and can be used in therapy. Gamma radiations have no mass or charge so they can penetrate the deep tissue of organs so used in diagnosis by imaging using a gamma camera. The radiopharmaceuticals were established in the diagnostic purpose and treatment of several diseases as thyroid gland cancer, hyperthyroidism, bone pain metastasis, kidney dysfunction, and myocardial and cerebral perfusion. The radioactive substance can also be used in the sterilization of thermo-labile substances as syringes, catheters, vitamins, hormones, and surgical dressing. The field of nuclear medicine has several advantages as localization of tumors, safe diagnosis, no accumulation of radiation, and high therapeutic efficacy. Nowadays, the branch of nuclear pharmacy is directed to introduce new radioactive pharmaceutical agents which will be important and effective in the treatment of cancer. The growth in the field of radiopharmaceuticals is important to help millions of patients suffering from tumors all over the world. The data of this review were collected by searching in Google Scholar and PubMed using the following keywords.

show abstract

Section: Introductionmentioning

confidence: 99%

Review About Radiopharmaceuticals: Preparation, Radioactivity, and Applications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cetuximab has been labeled with different radionuclides for diagnosis for instance technetium-99m (Schechter et al, 2004), gallium-68 (Evans et al, 2014) and zirconium-89 ( Van de Watering et al, 2014). For therapy, lutetium-177 (Jalilian et al, 2016) and yttrium-90 (Niu et al, 2010) have been used. Ping et al (2008) reported a preclinical study related to the use of cetuximab as a PET agent, directed to tumors overexpression` EGFR.…”

Section: Introductionmentioning

confidence: 99%

Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma

Benedetto¹,

Massicano²,

Silva³

et al. 2018

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Scientific innovations in diagnostic methods are important drivers of cancer control and prevention. Noninvasive imaging of the epidermal growth factor receptor (EGFR) in head-and-neck squamous, cell carcinoma and colorectal cancer could be valuable to select patients for EGFR-targeted therapy, as well as to monitor the efficacy and occurrence of resistance to immunotherapy. In order to develop the first Brazilian radioimmunoconjugate for diagnosis, Cetuximab has been conjugated to p-SCN-Bn-DTPA chelator and radiolabeled with Indium-111. The conjugation methodology was optimized using different mAb:DTPA molar ratios, time was then reduced for immunoconjugate preparation, besides the protein recovery' percentage increased after purification (m = 83.8 ± 0.91 %). The stability of Cetuximab-DTPA at -20 o C was evaluated for six months, and its integrity was greater than 90% (m =93.9 ± 1.5%, N = 24). The radioimmunoconjugate with specific activity of 185 MBq/mg showed radiochemical purity above 95% (m=96.8 ± 1.31 %, N = 15). We conclude that the radioimmunoconjugate 111In-DTPA-cetuximab is stable and may be applied to the diagnosis of EGFR-positive tumors.

show abstract